Brief: Finch Therapeutics Announces Decision To Discontinue Phase 3 Trial Of Cp101 And Focus On Realizing The Value Of Its Intellectual Property Estate And Other Assets
24/01/2023 13:23
Jan 24 (Reuters) - Finch Therapeutics Group Inc
FNCH.O :
* FINCH THERAPEUTICS ANNOUNCES DECISION TO DISCONTINUE PHASE
3
TRIAL OF CP101 AND FOCUS ON REALIZING THE VALUE OF ITS
INTELLECTUAL PROPERTY ESTATE AND OTHER ASSETS
* FINCH THERAPEUTICS ANNOUNCES DECISION TO DISCONTINUE PHASE
3
TRIAL OF CP101 AND FOCUS ON REALIZING THE VALUE OF ITS
INTELLECTUAL PROPERTY ESTATE AND OTHER ASSETS
* FINCH THERAPEUTICS GROUP INC - REDUCING ITS WORKFORCE BY
APPROXIMATELY 95%
* FINCH THERAPEUTICS GROUP INC - MAJORITY OF IMPACTED ROLES
WILL
END IN FEBRUARY 2023
Source text for Eikon: ID:nGNX3ml2R7
Further company coverage: FNCH.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp